throbber
Hyaluronic Acid Fillers in Facial Rejuvenation
`Mary P. Lupo, MD
`
`Nonsurgical procedures have become very popular for the rejuvenation of the aging face.
`Trends now are for less invasive procedures as well as for more preventative intervention
`to slow the damage from ultraviolet light and environmental factors, as well as from intrinsic
`aging. The goal of these procedures is to eliminate or delay the need for corrective surgery.
`The regular use of sunscreens; retinoids and improved cosmeceuticals; injectable neuro-
`toxins; soft-tissue augmentation products; and minimally invasive laser, light, and radio-
`frequency treatments are decreasing and delaying need for invasive procedures. Injectable
`fillers entered mainstream cosmetic medicine with the development of bovine collagen
`injections in the 1980s. The availability of improved fillers that are less allergenic and
`longer lasting has resulted in a renaissance in filler techniques. No single filler has proven
`to be more popular than the category of hyaluronic acids (HA). This article will review the
`use of the hyaluronic acid fillers that are currently approved for use by the Federal Drug
`Administration in the United States and describe the significant differences between them
`to assist the practicing cosmetic physician in choosing and using this category of dermal
`filler.
`Semin Cutan Med Surg 25:122-126 © 2006 Elsevier Inc. All rights reserved.
`
`Today’s cosmetic dermatologist is the specialist in nonsur-
`
`gical rejuvenation of the aging face. Many tools and tech-
`niques are available to achieve this goal. Although the process
`of skin aging is complex and beyond the scope of this review,
`it is sufficient to state that correction of aging skin requires a
`global approach that addresses the sequelae of both intrinsic
`(chronological) as well as extrinsic (primarily solar-induced)
`aging, using combination protocols.1
`Cosmeceuticals have been developed that mitigate the
`signs of photoaging, and this topic is explored more exten-
`sively in this issue. Topical antioxidants are available that
`reduce free radical damage to the skin, stimulate collagen
`production, improve color and texture, and decrease fine
`lines. Additional ingredients may improve the barrier func-
`tion of dehydrated, aging skin.2-4 It must always be remem-
`bered, however,
`that
`topical retinoids remain the gold
`standard in treating the visible signs of photoaging.5 Less-
`aggressive techniques to enhance the appearance of the skin
`include light chemical peels and particle resurfacing also
`known as “microdermabrasion.” These are popular because
`they are “no downtime” procedures.6,7 Injectable neurotoxins
`such as botulinum toxin type A dramatically improve wrin-
`kles that are the result of facial musculature movement.8 La-
`
`Department of Dermatology, Tulane Medical School, New Orleans, LA.
`Address correspondence to Mary P. Lupo, MD, Clinical Professor of Derma-
`tology, Tulane Medical School, New Orleans, Louisiana, 145 Robert
`E Lee Blvd., Suite 302, New Orleans, LA, 70124.
`
`122
`
`1085-5629/06/$-see front matter © 2006 Elsevier Inc. All rights reserved.
`doi:10.1016/j.sder.2006.06.011
`
`ser, pulsed noncoherent light, and other energy sources such
`as radiofrequency energy improve skin coloration, thicken
`dermal architecture, and tighten lax skin without cutting.9,10
`The final, and perhaps most popular, tool to add to combi-
`nation protocols for noninvasive facial rejuvenation is dermal
`fillers.
`
`Filler History
`For more than 20 years, the only fillers approved by the Food
`and Drug Administration (FDA) in the United States were
`forms of bovine collagen. Available in 3 forms, Zyderm I,
`Zyderm II, and the more highly cross linked Zyplast, they
`were our only realistic options for most patients wanting soft
`tissue augmentation. Allergic reaction rates were approxi-
`mately 3% before the adoption of 2 pretreatment skin
`tests.11,12 The availability of human-derived CosmoDermR
`and CosmoPlastR in March, 2003 obviated the need for skin
`testing and was a major breakthrough in esthetic dermatol-
`ogy. Patients could be treated at the time of consultation.
`Still, there was a need for fillers with greater longevity and
`more volume restoration than these collagen based products
`provided. Hyaluronic acid fillers, widely available outside of
`the United States, were the obvious choice to fill this need.
`The visible signs of
`facial aging partially result from
`changes in dentition and bony architecture. Facial fat loss
`and diminished dermal thickness from extrinsic (primarily
`photodamage) and intrinsic (the result of time and genetics)
`aging also contribute to the visible signs of aging. The addi-
`
`Exhibit 1005
`Prollenium v. Allergan
`
`

`

`Hyaluronic acid fillers in facial rejuvenation
`
`123
`
`Figure 1 A 28-year-old woman before restylane injection.
`
`Figure 2 The same woman 1 week after injection into nasolabial fold.
`
`tional loss of the collagen and the glycosaminoglycans (GAG)
`support structures that provide turgidity and support to the
`skin adds further to the appearance of aging. This loss of
`dermal and subcutaneous support results in folds and hol-
`lows that age the face. Filling concavities of the face with
`fillers such as the hyaluronic acids, restores a more youthful
`appearance without the need for cutting and redraping as is
`done with a face lift.
`
`Science of Hyaluronics
`Hyaluronic acid (HA) is one of the most prevalent glycosami-
`noglycans in the dermis, so its utility as a dermal filler is
`obvious. Because HA is not species specific, there is theoret-
`ically no need for skin testing for allergenicity. HA is a poly-
`saccharide composed of repeating units of D-glucuronic acid
`
`Figure 3 A 52-year-old African-American woman before injection.
`
`Figure 4 The same woman after Hylaform Plus and Restylane into
`nasolabial and marionette folds.
`
`

`

`124
`
`M.P. Lupo
`
`Figure 5 A 24-year-old woman.
`
`Figure 6 The same woman immediately after an injection of Hy-
`laform into the lips.
`
`and N-acetyl-glucosamine. It is found in all tissues of verte-
`brates and is very prevalent in human skin. It has been dem-
`onstrated to be decreased in intrinsically aged skin and to be
`altered in photoaged skin.13,14 HA is highly hydrophilic,
`binding much more than its weight in water. To be practical
`as a filler, however, crosslinking of the polysaccharide chains
`is necessary to slow degradation. Hyaluronic acid fillers are
`mainly used in the nasolabial fold, which was the site of
`original testing for FDA approval (Figs. 1 and 2). They are
`also commonly used “off label” in many other areas, includ-
`ing the lips and marionette folds (Figs. 3, 4, 5, and 6). Facial
`reshaping can be achieved by injecting HA into the cheek
`prominence and lateral brow. Advanced injectors place HA
`in the glabela crease, mental crease as well as the ocular
`sulcus and tear trough region.15
`Injection technique varies among injectors, with antegrade
`and retrograde threading as well as serial puncture being
`used. When injecting HA, it is important for the tip of the
`needle to be in the mid to deep dermis to avoid bluish dis-
`coloration or lumping that may be seen with superficial in-
`jections. Placement of HA too deeply in the dermis will com-
`promise the duration and extent of the correction obtained.
`Before injection near the orbital rim, it is important to aspi-
`rate the syringe to avoid inadvertent intravascular injection in
`this highly vascular region.
`At the present time, there are 4 HA fillers approved for use
`in the United States by the FDA. RestylaneR (Medicis Aesthet-
`ics Inc., Scottsdale, AZ), a nonanimal stabilized hyaluronic
`acid (NASHA) of medium viscosity for mid- to deep dermal
`correction, was the first approved in December 2003, fol-
`lowed by the approval of HylaformR, which is derived from
`rooster combs, in April 2004. Hylaform PlusR, formulated for
`deeper dermal injection was approved in October 2004 and
`CaptiqueTM followed in December 2004. A summary of the
`difference of these products is found in Table 1. Differences
`in molecular weight, particle size, and proprietary differences
`in crosslinking have resulted in theoretical variations in
`product behavior and duration. Some published experts be-
`lieve that Hylaform has characteristics that result in de-
`creased swelling and bruising.16 There is widespread anec-
`dotal reporting of greater duration with Restylane. A recent
`
`published report documented higher efficacy and patient sat-
`isfaction with Restylane over Hylaform after 12 weeks.17 An-
`other study showed more durable correction at six months
`with Restylane Perlane (a more viscous NASHA not currently
`available in the United States) over Hylaform.18 I have found
`benefit from layering medium-viscosity products such as Re-
`stylane in the mid dermis with larger particle Hylaform Plus
`in the deep dermis for those with deep nasolabial folds. Hy-
`laform can replace Cosmoderm in the higher dermis if in-
`jected with a fine gauge needle to fill more etched and fine
`skin lines.
`
`Complications
`There is no medical procedure totally devoid of risks. It is
`important to review all known potential side effects with the
`patient to obtain informed medical consent. Clinical trials
`have documented the overwhelming safety profile of all
`forms of HA.19 Transient and self-limiting redness and swell-
`ing are common following injections of HA and this is due to
`the hydrophilic nature of HA. For this reason, correction
`should never be greater than 100%. Pain associated with
`injection of HA may be managed by the use of both topical
`and injected anesthetic agents. This is especially important
`for lip injections where a superficial gingival block in the
`sulcus of the oral cavity provides one hour of anesthesia
`without the extended numbness and occasional morbidity
`seen with a nerve block. Despite adequate anesthesia, pa-
`tients can expect tenderness for 1 to 2 days after injection.
`Rarely do patients require treatment with analgesics.
`Nodule formation is possible after injection of any filler.
`Typically, this results from intermittent over-injection and
`the rate of nodule formation decreases with injector experi-
`ence. If nodule formation is noted, gentle massage may de-
`crease the appearance of the nodule but care should be taken
`to avoid over vigorous massage which will increase bruising.
`Bruising is, by far, the most common complication that is
`disturbing to patients (Fig. 7). Redness, swelling, and tender-
`ness usually fade after 24 hours, but bruising may persist for
`days and sometimes up to 1 week. One possible reason that
`
`

`

`Hyaluronic acid fillers in facial rejuvenation
`
`Table 1 Product Differences
`
`Source
`Concentration
`MW of raw HA
`Median particle size
`Polymer
`
`Restylane
`Bacterial
`20 mg/ml
`1.5–2 M
`300 microns
`Short chain, tight
`configuration
`BDDE
`Crosslink agent
`BDDE, 1,4-butandiol diglycidylether; DVS, divinyl sulfone.
`
`Hylaform
`Avian
`5.5 mg/ml
`4–6 M
`500 microns
`Long chain, loose
`configuration
`DVS
`
`Hylaform Plus
`Avian
`5.5 mg/ml
`4–6 M
`700 microns
`Long chain, loose
`configuration
`DVS
`
`125
`
`Captique
`Bacterial
`5.5 mg/ml
`1.5–2 M
`500 microns
`Short chain, tight
`configuration
`DVS
`
`HA causes more bruising is its structurally similar to heparin.
`Baumann has advocated the use of collagen injection along
`with the HA to reduce bruising.20 She postulates that the
`lidocaine in the Cosmoderm or Cosmoplast has an antibruis-
`ing benefit, but there have been no controlled studies to
`substantiate this hypothesis. Lidocaine is known to decrease
`the activation of eosinophils that may stimulate bruising.21
`Reducing the number of needle sticks in a given treatment
`has decreased bruising in my practice and is one reason I
`recommend threading over serial puncture with HA fillers.
`Finally, true allergic reactions to HA have been reported.22,23
`Treatment with intralesional and topical corticosteroids as
`well as topical immune modulating agents have been tried
`with limited success.23,24 One of the unique benefits of utiliz-
`ing HA fillers is the ability to correct lumps and even elimi-
`nate allergic responses by the injection of hyaluronidase to
`enzymatically degrade the HA filler quickly. Hyaluronidase
`injections are the treatment of choice to reverse allergic reac-
`tions.24,25
`
`The Future
`It is reasonable for the practicing esthetic physician to expect
`additional fillers to be available in the US over the next several
`years. European and Canadian physicians have experience
`with other forms of Restylane such as Perlane for deep dermal
`and subcutaneous correction and Restylane Touch for papil-
`lary dermal correction of fine lines. A smaller particle form of
`Hylaform may come to the U.S. market as well. Another HA
`
`Figure 7 A bruise is evident 3 days after restylane injection.
`
`filler, Juvederm, is widely available and popular outside the
`US and is being evaluated for FDA approval. Discussion of
`this product in this article is not appropriate since it is cur-
`rently undergoing FDA evaluation, but experts report excel-
`lent cosmetic correction with natural softness combined with
`long duration.26,27
`What is clear is that worldwide usage and published re-
`ports confirm the efficacy and safety of hyaluronic acid fillers.
`Popularity of such fillers continues to increase as the aging
`population seeks options to correct the signs of aging without
`surgery. Fillers such as the hyaluronic acids are obviously one
`of the key components to the successful combination treat-
`ment of the aging face.
`
`References
`1. Lupo MP: Photoaging threat advisory: a treatment algorithm. Cosmetic
`Dermatol 18:221-224, 2005
`2. Darr D, Combs S, Dunston S, et al: Effectiveness of antioxidants (vita-
`min C and E) with and without sunscreens as topical photoprotectants.
`Acta Dermatol Venereol 76:264-268, 1996
`3. Tanno O, Ota Y, Kitamura N, et al: Nicotinamide increases biosynthesis
`of ceramides as well as other stratum corneum lipids to improve the
`epidermal permeability barrier. Br J Dermatol 143:524-531, 2000
`4. Elmets CA, Singh D, Tubesing K, et al: Cutaneous photoprotection
`from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol
`44:425-432, 2001
`5. Kligman AM, Grove JL, Hirose R, et al: Topical tretinoin for photoaged
`skin. J Am Acad Dermatol 15:836-859, 1986
`6. Moy LS, Murad H, Moy RL: Glycolic acid peels for the treatment of
`wrinkles and photoaging. J Dermatol Surg Oncol 19:243-246, 1993
`7. Comite SL, Krishtul A, Tan MH: Using microdermabrasion to treat
`sun-induced facial lentigines and photoaging. Cosmetic Dermatol 16:
`40-42, 2003
`8. Klein A: The art and science of treating facial wrinkles with botulinum
`toxin A. J Am Acad Dermatol 53:364-365, 2005
`9. Bitter PH: Noninvasive rejuvenation of photodamaged skin using serial,
`full-faced intense pulsed light treatments. Dermatol Surg 26:835-843,
`2000
`10. Fisher GH, Jacobson LG, Bernstein LJ, et al: Nonablative radiofre-
`quency treatment of facial laxity. Dermatol Surg 31:1237-1241, 2005
`11. Cooperman LS, Mackinnon V, Bechler G, et al: Injectable collagen: a six
`year clinical investigation. Aesthetic Plast Surg 9:145-151, 1985
`12. Klein AW: In favor of double testing. J Dermatol Surg Oncol 15:263,
`1989
`13. Ghersetich I, Lotti T, Campanile G, et al: Hyaluronic acid in cutaneous
`intrinsic aging. Int J Dermatol 33:119-122, 1994
`14. Bernstein EF, Underhill CB, Hahn PJ, et al: Chronic sun exposure alters
`both the content and distribution of dermal glycosaminoglycans. Br J
`Dermatol 135:255-262, 1996
`15. de Maio M: The minimal approach: an innovation in facial cosmetic
`procedures. Aesth Plast Surg 28:295-300, 2004
`
`

`

`126
`
`M.P. Lupo
`
`16. Baumann L: Replacing dermal constituents lost through aging with
`dermal fillers. Semin Cutan Med Surg 20:125-128, 2004
`17. Rao J, Chi GC, Goldman MP: Clinical comparison between two hyal-
`uronic acid-derived fillers in the treatment of nasolabial folds: hylaform
`versus restylane. Dermatol Surg 31:1587-1590, 2005
`18. Carruthers A, Carey W, DeLorenzi C, et al: Randomized, double-blind
`comparison of the efficacy of two hyaluronic acid derivatives, restylane
`perlane and hylaform, in the treatment of nasolabial folds. Dermatol
`Surg 31:1591-1598, 2005
`19. Narins RS, Brandt F, Leyden J, et al: A randomized, double-blind,
`multicenter comparison of the efficacy and tolerability of restylane
`versus Zyplast for the correction of nasolabial folds. Dermatol Surg
`29:588-595, 2003
`20. Baumann L. Cosmoderm/Cosmoplast (human bioengineered collagen)
`for the aging face. Facial Plast Surg 20:125-128, 2004
`21. Okada S, Hagan JB, Kato M, et al: Lidocaine and its analogues inhibit
`
`and activation of human eosinophils.
`IL-5-mediated survival
`J Immunol 160:4010-4017, 1998
`22. Lupton JR, Alster TS: Cutaneous hypersensitivity reaction to injectable
`hyaluronic acid gel. Dermatol Surg 26:135-137, 2000
`23. Lowe NJ, Maxwell CA, Lowe P, et al: Hyaluronic acid fillers: adverse
`reactions and skin testing. J Am Acad Dermatol 45:930-933, 2001
`24. Brody HJ: Use of hyaluronidase in the treatment of granulomatous
`hyaluronic acid reactions or unwanted hyaluronic acid misplacement.
`Dermatol Surg 31:893-897, 2005
`25. Soparkur CNS, Patrinely JR: Managing inflammatory reactions to re-
`stylane. Opthal Plast Reconstr Surg 21:151-153, 2005
`26. Zbili M: Personal experience in the filling of wrinkles and remodeling
`lips with Juvederm. J de Med Esthet Chir Dermatol 29:241-246, 2002
`(translation)
`27. Saylan Z: Facial fillers and their complications. Aesthetic Surg J 23:221-
`224, 2003
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket